Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
about
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsAddition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 TrialLong-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Dapagliflozin for the treatment of type 2 diabetes: a review of the literatureIpragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the potBeneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes.Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.Adenylyl Cyclase Type 5 Deficiency Protects Against Diet-Induced Obesity and Insulin ResistanceIpragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 DiabetesFactors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K StudyImpact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes MellitusSubstantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled StudyAn overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsRationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.SGLT-2 inhibitors and their potential in the treatment of diabetes.Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial.Potential benefits of rho-kinase inhibition in arterial hypertension.The importance of synthetic drugs for type 2 diabetes drug discovery.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.Luseogliflozin for the treatment of type 2 diabetes.Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phaIpragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-liEffectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.Clinical implications of canagliflozin treatment in patients with type 2 diabetes.Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus.Protein tyrosine phosphatase 1B deficiency in podocytes mitigates hyperglycemia-induced renal injury.Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent.
P2860
Q26772081-43E44B22-2C27-4C3E-B407-0958ED9E9FEFQ27027105-E43D7DF5-D341-4427-89F4-076A736FD294Q28072765-4B2C31A4-B583-4745-A814-588CA882FA97Q33614337-5BBA4EB7-CA16-4F8C-8E35-0CA9788A31F7Q33885732-0FE2A8C1-BA4B-42C8-A0DB-C2F308D6A03DQ34543009-4AB5E31F-C6A1-4753-8719-6F05FFAE1027Q34710819-6FC9448B-73FD-41A6-A3F7-9CF58B6EC03BQ35049845-46960ED7-7DAA-4729-B1E1-0CF78F4E5AC6Q35192356-3531E0C2-B07D-479C-8742-1EA221E2D4F6Q35548033-D781BE40-D222-462D-A2B4-107B81E185DFQ35558413-A99B1A03-2D81-4474-BDD8-7D7944CC16EBQ35769605-A3617B01-B81E-4413-91F0-A371371AD9EEQ35957448-422D091F-C822-49EE-8F16-ABF2A8732F72Q36257199-A806A9F7-D6EF-4BF7-B15E-402FE1CFDA8BQ36756191-423CA54F-4320-4B0C-83D6-B996F8889D29Q36804248-4EB91842-6A1B-4F5D-9094-E4DA7AEA4774Q37080615-2F2C38CC-FA08-4B78-98C6-1D4F7FFE48B4Q37114983-8CF85092-F7B2-4654-8ABA-771C1C7693A6Q37251449-206E0E5E-4050-4EDC-9536-F4283296F51BQ37359631-9E2F653D-CB08-4196-9B00-567D632C498CQ37421058-36512173-BDAC-4282-AC06-415CAF1AA09CQ37653114-0A38D678-CE77-4911-A473-1A3A867A6702Q38121505-3B014D34-4C1D-4E51-A392-070470243878Q38139508-618673CD-1F74-406D-BE78-0E2DFE58ED04Q38175467-FF7D77F9-C553-4A91-BCB0-AEBB100FF0BAQ38196340-68176300-8955-4D6A-AFA5-4C721B25C5ECQ38254252-0C309E00-FE1D-451C-99E8-97F74129B760Q38264051-A6D9461E-0B3C-4ECA-AC60-B9E3823D6CDDQ38270203-CF2E5F3F-85D1-481B-A53E-69CDBCE22006Q38537119-5B057071-C0FC-4594-B147-8455546EB702Q39245449-4EB8CCD9-1AA7-4130-AA91-B22ADDC7868EQ39296548-65851B2F-A4B5-420F-96E3-03D3EBB77138Q39879822-B3437239-7140-432A-ABAF-79BB81223445Q39969038-CD407FCE-306E-43C4-B725-5F042B52EBDFQ40091881-3F9CAAF3-0F66-4CE7-B036-91DE74949830Q41258175-1D40CBB2-CEFA-4B51-BD89-31B56DAF69E9Q41476579-187F8D08-EE9B-4D71-AD1A-58016A3E64ECQ46207930-E3146063-F3D3-4D95-ACFB-A006E4DD14B6Q46411006-8201D302-2E49-4B2E-8551-ECA82929F39BQ46650678-620A37C7-CB6A-4043-846B-50DAC07A8B8D
P2860
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Ipragliflozin and other sodium ...... preclinical and clinical data.
@ast
Ipragliflozin and other sodium ...... preclinical and clinical data.
@en
type
label
Ipragliflozin and other sodium ...... preclinical and clinical data.
@ast
Ipragliflozin and other sodium ...... preclinical and clinical data.
@en
prefLabel
Ipragliflozin and other sodium ...... preclinical and clinical data.
@ast
Ipragliflozin and other sodium ...... preclinical and clinical data.
@en
P921
P1476
Ipragliflozin and other sodium ...... preclinical and clinical data.
@en
P2093
Eiji Kurosaki
Hideaki Ogasawara
P356
10.1016/J.PHARMTHERA.2013.04.003
P577
2013-04-04T00:00:00Z